Holen Sie sich die Stockscreener-App
25.90
0.19%
-0.05
Vorhandelsmarkt:
25.90
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer (PFE) Valuation Check After New HYMPAVZI Approval Vaccine Data And Oncology Collaboration - simplywall.st
[Latest] Global Bioprocess Automation Software Market Size/Share Worth USD 6.19 Billion by 2035 at a 14 CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
How The Investment Narrative For Pfizer (PFE) Is Shifting On Pipeline Hopes And Revenue Risks - Yahoo Finance
Spotting Winners: Pfizer (NYSE:PFE) And Branded Pharmaceuticals Stocks In Q1 - Yahoo Finance
Pfizer Inc. stock (US7170811035): Cancer focus and pipeline updates keep investors watching PFE - AD HOC NEWS
Pfizer's CEO uses AI to make his biggest calls — and 64% of CEOs agree, quietly shifting your portfolio - Yahoo Finance
Why 1 Wall Street Analyst Thinks Pfizer (PFE) Stock Could Soar 38% - The Globe and Mail
Pfizer, Inc. (PFE) Stock Analysis: Exploring a 12.69% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews
Pfizer stock (US7170811035): oncology collaboration and cautious recovery draw fresh attention - AD HOC NEWS
What's the Better Dividend Stock Today: AbbVie or Pfizer? - Yahoo Finance
Pfizer Inc To Discuss Data From An Ongoing Phase 1/2 Study Of mRNA-Based Vaccine Candidate Against SARS-CoV-2 Call Transcript - GuruFocus
Pfizer Oncology Partnerships Add Detail To Valuation And Earnings Concerns - Yahoo Finance UK
Pfizer Collaboration Targets Faster Cancer Trials While Shares Trade Below Value - simplywall.st
Pfizer’s SWOT analysis: stock navigates patent cliff with new drugs By Investing.com - Investing.com UK
The Most Important Healthcare Stock You're Not Watching - Yahoo Finance
PFE Stock Quote Price and Forecast - CNN
Pfizer Tests New Tafamidis Tablet Forms in Phase 1 Bioequivalence Study - TipRanks
Pfizer class action alleges website tracked users despite cookie opt-outs - Class Action Lawsuits
J&J & Pfizer Face Patent Risks: Which Stock Looks Better Positioned? - Yahoo Finance Singapore
Is Trending Stock Pfizer Inc. (PFE) a Buy Now? - Yahoo Finance
TREM2 agonists detailed in Pfizer patent - BioWorld News
Here’s Why Pfizer (PFE) Is One of the Most Undervalued US Stocks - Yahoo Finance
Pfizer: Reduced TrumpRx/Patent Risks Meet Accretive M&A EffortsReiterate Buy (NYSE:PFE) - Seeking Alpha
Kimberly-Clark (KMB) vs Pfizer (PFE): Defensive Dividend Showdown for 2026 - Gotrade
Pfizer wins Singapore trademark dispute with Merck over vaccine brand - The Straits Times
PFE.DE Technical Analysis | Trend, Signals & Chart Patterns | PFIZER INC (FRA:PFE) - ChartMill
Pfizer Inc. stock (US7170811035): vaccine data and hemophilia approval put pharma giant back in focu - AD HOC NEWS
Pfizer Inc. Trade Ideas — BX:PFEUSD - TradingView
Goldman Sachs Maintains Pfizer(PFE.US) With Hold Rating, Maintains Target Price $26 - Moomoo
Building an AI-Fluent Organization: How Pfizer is helping colleagues understand, embrace, and apply AI - Pfizer
Building an AI-Literate Organization: How Pfizer is helping colleagues understand, embrace, and apply AI - Pfizer
Pfizer (PFE) Valuation Check After HYMPAVZI Expansion And Positive Pneumococcal Vaccine Data - Yahoo Finance
Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026 Featuring Major Players Novo Nordisk A/S, Eli Lilly and Company, and PfizerGlobal Forecast to 2030 and 2035 - Yahoo Finance Singapore
Comirnaty vaccine guide: how Pfizer's mRNA shot works - AD HOC NEWS
BMO Capital Maintains Pfizer(PFE.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Is Vaccine And Hematology Progress Reshaping The Investment Case For Pfizer (PFE)? - simplywall.st
Pfizer’s Broader Pneumococcal Vaccine Push Might Change The Case For Investing In Pfizer (PFE) - Yahoo Finance
Pfizer’s VEPPANU License With Rigel Adds New Angle To PFE Story - Yahoo Finance
Pfizer stock (US7170811035): new pediatric vaccine data and structured note spotlight long-term bets - AD HOC NEWS
Sarah Cannon Research Institute Announces Strategic Oncology Research Collaboration with Pfizer - BioSpace
EBITDA of Pfizer Inc. – BVL:PFEUS - TradingView
Equity in earnings of Pfizer Inc. – BVL:PFEUS - TradingView
Pfizer Inc. Revenue Breakdown – BVL:PFEUS - TradingView
Pfizer Inc. Financial Statements – BVL:PFEUS - TradingView
Pfizer Inc. Income Statement – BVL:PFEUS - TradingView
ETFs Investing in Pfizer Inc. Stocks - TradingView
Free float of Pfizer Inc. – BVL:PFEUS - TradingView
Pfizer Moves Next-Gen Vaccine Into Phase III In Prevnar Lifecycle Strategy - Citeline News & Insights
Pfizer Options Spot-On: On May 20th, 91,964 Contracts Were Traded, With 2.54 Million Open Interest - Moomoo
Sarah Cannon Research Institute inks partnership with Pfizer - Nashville Post
Pfizer Inc (PFE) Stock Price, Trades & News - GuruFocus
FQ1 Healthcare Dividend Roundup: Johnson & Johnson Keeps Outshining Pfizer (NYSE:PFE) - Seeking Alpha
Three Dividend-Paying Healthcare Giants: Pfizer (PFE), AbbVie (ABBV), and Medtronic (MDT) Compared for 2026 - Blockonomi
High Yield Healthcare Stocks: Why Pfizer, AbbVie, and Medtronic Are Worth Watching in 2026 - CoinCentral
Pfizer Builds Oncology Growth Around Padcev and Pipeline Expansion - Yahoo Finance
Sarah Cannon Research Institute announces strategic oncology research collaboration with Pfizer - marketscreener.com
Pfizer Expands Pneumococcal Vaccine Push With New Programs - Benzinga
Sarah Cannon Research Institute and Pfizer Announce Strategic Oncology Research Collaboration - marketscreener.com
Research Rising: Recognizing Clinical Trials Day 2026 - Pfizer
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results - BioSpace
Pfizer begins late-stage trial for new pneumococcal shot in infants after strong Phase 2 data - Seeking Alpha
Pfizer Stock Shares $49 Bil Success With Investors - Trefis
Pfizer Stock at $25: A $29 Wall Street Mean Target Backed by Two Legal Wins and 22% Portfolio Growth - TIKR.com
Pfizer's pneumococcal shot shows stronger immune response in mid-stage trial - Reuters
2.96%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):